Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | CETP | P11597 | 7/20 | 0.75 |
| ▸ | MEN1 | O00255 | 4/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.75 |
| ▸ | THRB | P10828 | 3/20 | 0.75 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.73 |
| ▸ | ASAH2 | Q9NR71 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.55 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.55 |
| ▸ | GMNN | O75496 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetyl Ceramide SCHEMBL21067736 | 1.00 | MAPT (1.00) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| Acetyl Ceramide SCHEMBL31683764 | 1.00 | MAPT (1.00) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| Acetyl Ceramide SCHEMBL12648655 | 1.00 | MAPT (1.00) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL12330743 | 1.00 | MAPT (1.00) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| Acetyl Ceramide SCHEMBL16892474 | 1.00 | MAPT (1.00) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| Acetyl Ceramide SCHEMBL1191825 | 1.00 | MAPT (1.00) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| Acetyl Ceramide SCHEMBL29144648 | 1.00 | MAPT (1.00) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| Acetyl Ceramide SCHEMBL29756043 | 1.00 | MAPT (1.00) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL12764186 | 0.90 | MAPT (0.81) | MAPTCYP2D6MAPK1TP53CYP1A2 | |
| SCHEMBL8622716 | 0.88 | MAPT (0.78) | MAPTCYP2D6MAPK1TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 635 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223352-B1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | UROTRONIC INC (US) | 2026-05-27 | — | — | EP | claimed |
| US-12605342-B2 | Polymer-encapsulated drug particles | TONIC MEDICAL, INC. (US) | 2026-04-21 | — | — | US | claimed |
| CN-116508751-B | Method for preventing and controlling harmful algae in water body by using sphingosine substances | 浙江大学 | 2025-05-13 | — | — | CN | claimed |
| US-12280226-B2 | Drug-coated balloon catheters for body lumens | UROTRONIC, INC. (US) | 2025-04-22 | — | — | US | claimed |
| CN-119733157-A | Drug coated balloon catheter for non-vascular stenosis | 江苏长寿棒科技有限公司 | 2025-04-01 | — | — | CN | claimed |
| US-20250082582-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | TONIC MEDICAL, INC. | 2025-03-13 | — | — | US | claimed |
| US-20250025673-A1 | METHOD FOR TREATMENT OF AIRWAY STRICTURE OR STENOSIS | AIRIVER MEDICAL, INC. | 2025-01-23 | — | — | US | claimed |
| CN-119303213-A | Drug-coated balloon catheter for body cavities | 优敦力公司 | 2025-01-14 | — | — | CN | claimed |
| US-20240416013-A1 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | UROTRONIC, INC. | 2024-12-19 | — | — | US | claimed |
| US-12168108-B2 | Balloon catheters for body lumens | UROTRONIC, INC. (US) | 2024-12-17 | — | — | US | claimed |
| US-20100056482-A1 | Calixarene Derivatives as Anticancer Agent | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2010-03-04 | — | — | US | claimed |
| US-20090196859-A1 | Oligodendrocyte Precursor Cell Composition and Methods of Use | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE (US) | 2009-08-06 | — | — | US | claimed |
| US-7445931-B2 | Culturing differentiating pluripotent human cell with N-palmitoyl serinol or N-oleoyl serinol in serum-free medium; modulating apoptosis | BRESAGEN, INC. (US) | 2008-11-04 | — | — | US | claimed |
| EP-1250119-B1 | REDUCTION OF HAIR GROWTH | GILLETTE CO (US) | 2007-10-03 | — | — | EP | claimed |
| WO-2004080478-A1 | THERAPEUTIC AND PROPHYLACTIC COMPOSITIONS AND USES THEREFOR | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2004-09-23 | — | — | WO | claimed |
| US-6204006-B1 | TREATING PARENT STRAIN OF YEAST WHICH NATURALLY PRODUCES TETRAACETYLPHYTOSPHINGOSINE WITH A MUTAGEN AND SELECTING HIGH YIELD MUTANT STRAIN; FOR PRODUCTION OF AT LEAST 0.030 GRAMS PER YEAST DRY WEIGHT FROM SHAKING, LIQUID CULTURE | DSM, N.V. (NL) | 2001-03-20 | — | — | US | claimed |
| EP-0850056-A1 | TOPICAL ANTI-SKIN-CANCER PREPARATIONS | Beiersdorf Aktiengesellschaft (DE) | 1998-07-01 | — | — | EP | claimed |
| WO-1997009975-A1 | TOPICAL ANTI-SKIN-CANCER PREPARATIONS | BEIERSDORF AG (DE) | 1997-03-20 | — | — | WO | claimed |
| EP-0736770-A2 | An immunoreactive conjugate, method for its preparation, antibodies to said conjugate and a pharmaceutical composition and diagnostic device containing them | ANDA BIOLOGICALS S.A. (FR) | 1996-10-09 | — | — | EP | claimed |
| US-5260288-A | Administering an inflammation inhibitory amount | THE BIOMEMBRANE INSTITUTE (US) | 1993-11-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605342-B2 | Polymer-encapsulated drug particles | MUC1, SLC10A2, EGFR | MAPT 940/4885CYP2D6 1296/4885MAPK1 3225/4885 |
| US-20100056482-A1 | Calixarene Derivatives as Anticancer Agent | CALU, CALR, CALD1 | MAPT 3476/4885CYP2D6 2092/4885MAPK1 1626/4885 |
| US-20250082582-A1 | POLYMER-ENCAPSULATED DRUG PARTICLES | CD47, GRPR, HSPA5 | MAPT 1693/4885CYP2D6 2886/4885MAPK1 3616/4885 |
| US-20090196859-A1 | Oligodendrocyte Precursor Cell Composition and Methods of Use | SGMS1, S1PR1, S1PR3 | MAPT 4359/4885CYP2D6 4804/4885MAPK1 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.